"Coincidence or phenomena? The reovirus is Mother Nature's own cancer-killer." Provocative headlines from PharmExec.com.
Read the full article here.
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Search
Events
About Oncolytics Biotech, Inc.
Oncolytics Biotech Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers. Headquartered in Calgary, Alberta, Canada, the Company was formed in 1998 to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer.
Reolysin, the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders.
from oncolyticsbiotech.com
Reolysin, the company's proprietary formulation of the human reovirus, has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. Reolysin may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders.
from oncolyticsbiotech.com
Links
About Me
- Author
- I am an owner of Oncolytics Biotech Inc. stock (ONCY). This blog was created to serve as an archive of information, events, and news regarding this exciting company seeking novel treatments and cures for cancer.
Bulletin
If you would like to become a contributor, write articles, or post links, etc., Contact me at oncy.man@gmail.com to be added as an author.
And of course feel free to leave a comment anytime.
And of course feel free to leave a comment anytime.
disclaimer
oncolytics.blogspot.com is a privately published webpage and is in no way affiliated or sanctioned by Oncolytics Biotech Corp. None of the information contained in this blog constitutes a recommendation to buy or sell any stock or security. The author is an owner of ONCY stock and may buy or sell additional shares from time to time.
No comments:
Post a Comment